Duchenne Muscular Dystrophy (DMD) Treatment Market: By Drug Class(Corticosteroids, Pain management drugs) By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Duchenne Muscular Dystrophy Treatment Market size was estimated at USD 3.8 Bn in 2022, growing at a CAGR of 38.2% from 2023-2029. Duchenne muscular dystrophy (DMD) is a genetic disorder and it is one of the 9 types of muscular dystrophy, which is characterized by progressive degeneration and weakness of muscle. It is caused due to the absence of dystrophin protein which helps to keep muscle cells intact. The onset of symptoms will be from early childhood in the age of 3-5. Guillaume Benjamin Amand Duchenne was the first French neurologist to describe Duchenne muscular dystrophy in the 1860s. There is no known cure for Duchenne muscular dystrophy but the treatment is given to control the symptoms to maximize the quality of life of the patient. There are very few products marketed for the treatment of Duchenne muscular dystrophy-like Translama, Exodus 51, and Emflaza. Presently this market is in the research phase majorly and focuses on the ongoing clinical trials for the development of innovative products. Government organizations are focussing on the prevention of Duchenne muscular dystrophy. For instance, world Duchenne Awareness Day was initiated by The United Parent Projects Muscular Dystrophy (UPPMD) with the motto of rising awareness regarding Duchenne muscular dystrophy globally and they have declared 07 th September as the World's Duchenne Awareness Day. In 2015, U.S. FDA published specific guidance for the development of drugs to treat Duchenne muscular dystrophy. Innovative approaches like utrophin modulation which is going to launch during the forecast period to treat DMD and approvals for drugs such as ezutromid of summit therapeutics a phase II clinical trial drug that received orphan drug designation fast approval from U.S.FDA and BioMarin Pharmaceuticals is developing an exon-skipping drisapersen which is phase III clinical trial evaluation all these developments are expected to offer lucrative opportunities for Duchenne Muscular Dystrophy Treatment Market.

Global Duchenne Muscular Dystrophy Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

38.2%

Largest Market

Europe

Fastest Growing Market

North America
Duchenne Muscular Dystrophy Treatment Market Dynamics

Increase in the prevalence rate of duchenne muscular dystrophy is the major factor expected to drive the market growth of Market. As per, NHS estimation 100 are born with duchenne muscular dystrophy every year in the UK, while 349 new cases were reported in the U.S. in 2010 as per to Centre for Disease Control. Furthermore, Increasing in healthcare expenditure and growing awareness about Duchenne muscular dystrophy is also propelling the growth of the Market. However, low treatment seeking rate because of delayed diagnosis and fast prognosis of the disorder are the factors which are restraining the growth of Duchenne muscular dystrophy.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Duchenne Muscular Dystrophy Treatment Market Segmentation

By Drug Class
  • Corticosteroids
  • Pain management
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Geography

North America

  1. USA
  2. Canada

Europe

  1. Germany
  2. France
  3. UK
  4. Italy
  5. Spain
  6. Russia
  7. Poland
  8. Rest of Europe

Asia-Pacific

  1. Japan
  2. China
  3. India
  4. Australia & New Zealand
  5. ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  6. South Korea
  7. Rest of Asia-Pacific

Latin America

  1. Brazil
  2. Mexico
  3. Argentina
  4. Rest of Latin America

Middle East and Africa (MEA)

  1. Gulf Cooperation Council (GCC) Countries
  2. Israel
  3. South Africa
  4. Rest of MEA

 

Frequently Asked Questions

The duchenne muscular dystrophy treatment market was valued at USD 3.8 billion in 2022

The duchenne muscular dystrophy treatment market key players are: Bristol-Myers Squibb(U.S) FibroGen, Inc (U.S) ITALFARMACO S.p.A. (Italy) Catabasis Pharmaceuticals, Inc.(U.S) NS Pharma, Inc. (U.S) Marathon Pharmaceuticals, LLC (U.S) ReveraGen BioPharma, Inc. (U.S) Pfizer (U.S) Summit Therapeutics plc (U.K) Taiho Pharmaceutical Co (Japan) Sarepta Therapeutics, Inc. (U.S) Santhera Pharmaceuticals PTC Therapeutics (Switzerland)

The duchenne muscular dystrophy treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

  1. Executive Summary
  2. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Introduction
    • Global Duchenne Muscular Dystrophy (DMD) Treatment Market Taxonomy
    • Global Duchenne Muscular Dystrophy (DMD) Treatment Market Definitions
      • Drug Class
      • Distribution Channel
  1. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamic Factors - Impact Analysis
    • Global Duchenne Muscular Dystrophy (DMD) Treatment Market Competition Landscape
    • Epidemiology
  2. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis,2018 - 2022 and Forecast, 2023 - 2029
    • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Duchenne Muscular Dystrophy (DMD) Treatment Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Corticosteroids
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Pain management drugs
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Hospital Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Duchenne Muscular Dystrophy (DMD) Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Region, 2018 2024
  2. North America Duchenne Muscular Dystrophy (DMD) Treatment MarketAnalysis,2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Corticosteroids
      • Pain management drugs
    • Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2016 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America Duchenne Muscular Dystrophy (DMD) Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2018 2024
    • North America Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics Trends
  3. Europe Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Corticosteroids
      • Pain management drugs
    • Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Duchenne Muscular Dystrophy (DMD) Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2018 2024
    • Europe Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics Trends
  4. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Corticosteroids
      • Pain management drugs
    • Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Duchenne Muscular Dystrophy (DMD) Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2018 2024
    • Asia-Pacific Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics Trends
  5. Latin America Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Corticosteroids
      • Pain management drugs
    • Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Duchenne Muscular Dystrophy (DMD) Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2018 2024
    • Latin America Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics Trends
  6. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Corticosteroids
      • Pain management drugs
    • Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Duchenne Muscular Dystrophy (DMD) Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2018 2024
    • MEA Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Bristol-Myers Squibb(U.S)
      • FibroGen, Inc (U.S)
      • ITALFARMACO S.p.A. (Italy)
      • Catabasis Pharmaceuticals, Inc.(U.S)
      • NS Pharma, Inc. (U.S)
      • Marathon Pharmaceuticals, LLC (U.S)
      • ReveraGen BioPharma, Inc. (U.S)
      • Pfizer (U.S)
      • Summit Therapeutics plc (U.K)
      • Taiho Pharmaceutical Co (Japan)
      • Sarepta Therapeutics (U.S), Inc.
      • Santhera Pharmaceuticals
      • PTC Therapeutics (Switzerland).
  1. Research Methodology
  2. Key Assumptions and Acronyms

 

  • Bristol-Myers Squibb(U.S)
  • FibroGen, Inc (U.S)
  • ITALFARMACO S.p.A. (Italy)
  • Catabasis Pharmaceuticals, Inc.(U.S)
  • NS Pharma, Inc. (U.S)
  • Marathon Pharmaceuticals, LLC (U.S)
  • ReveraGen BioPharma, Inc. (U.S)
  • Pfizer (U.S)
  • Summit Therapeutics plc (U.K)
  • Taiho Pharmaceutical Co (Japan)
  • Sarepta Therapeutics, Inc. (U.S)
  • Santhera Pharmaceuticals
  • PTC Therapeutics (Switzerland)

Adjacent Markets